Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID‐19

ABSTRACT Molnupiravir, an orally administered drug for the treatment of mild‐to‐moderate COVID‐19, is a prodrug of the ribonucleoside β‐D‐N4‐hydroxycytidine (NHC). NHC incorporation in the SARS‐CoV‐2 RNA strand causes an accumulation of deleterious errors in the genome, resulting in reduced viral in...

Full description

Saved in:

Bibliographic Details
Main Authors:	Akshita Chawla, Ruthie Birger, Brian M. Maas, Youfang Cao, Hong Wan, Julie Strizki, Arthur Fridman, Amanda Paschke, Carisa deAnda, Wei Gao, Matthew L. Rizk, Wendy Painter, Wayne Holman, Susanne Sardella, George Painter, Julie A. Stone
Format:	Article
Language:	English
Published:	Wiley 2025-04-01
Series:	Clinical and Translational Science
Subjects:	β‐D‐N4‐hydroxycytidine exposure‐response low‐frequency nucleotide substitutions NHC pharmacokinetics‐pharmacodynamics SARS‐CoV‐2
Online Access:	https://doi.org/10.1111/cts.70184
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID‐19

Similar Items